This is a working overview of triple agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-01. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
=== Founding and early years === On June 20, 1919, Roy W. Allen opened his first root beer stand in Lodi, California. The first day was for a homecoming celebration of soldiers who returned from battle in World War I. The following day, his stand was open for regular customers, selling root beer glasses for 5 cents (equivalent to $0.93 in 2025). The following year, Allen opened a second stand in Stockton, California. Shortly afterward, the effect of the period of prohibition that existed in the United States from 1920 to 1933 gave Allen and his stand with a beverage with "beer" in the name a heavy rebound. Four years later, A&W began when Allen and Frank Wright opened their drive-in restaurant in Sacramento, California, combining both of their initials for the name, and selling the root beer from Allen's stand. Curbside service was provided by tray boys and tray girls. In 1924, Allen purchased Frank Wright's stake in the business. In 1925, Allen began franchising the root beer, while the franchisee added the other menu items and operated at their discretion. Most of the restaurants that opened under this scheme were on the highways of the Central Valley region, mainly for travelers. This may have arguably been the first successful food-franchising operation. Allen sold the company in 1950 and retired. A lot of World War I veterans eventually founded A&W franchises throughout the US, while some of their descendants still own franchises. A&W's initial menu relied heavily on root beer and snacks, such as popcorn and peanuts, as well as sandwiches on sliced bread. In 1927, J.
== Social initiatives == IDLO is a long-time sponsor of various endurance and outdoor events, including Gorgany Race, the Night Chornohora Marathon, Stezhkamy Heroiv, and Spartan Race. The company also partners with educational camps organized by the Ukrainian national scouting organization Plast. Since 2020, IDLO has led an environmental program called “Leave No Trace”, to improve waste management in the Ukrainian mountains. The company accepts used doypacks for recycling, including those from other manufacturers. Following the full-scale Russian invasion of Ukraine in 2022, company co-founders Mykhaylo Temper and Serhii Andrieiev joined the Armed Forces of Ukraine.
== Definition == Hypoglycemia, also called low blood sugar or low blood glucose, is a blood-sugar level below 70 mg/dL (3.9 mmol/L). Blood-sugar levels naturally fluctuate throughout the day, the body normally maintaining levels between 70 and 110 mg/dL (3.9–6.1 mmol/L). Although 70 mg/dL (3.9 mmol/L) is the lower limit of normal glucose, symptoms of hypoglycemia usually do not occur until blood sugar has fallen to 55 mg/dL (3.0 mmol/L) or lower. The blood-glucose level at which symptoms of hypoglycemia develop in someone with several prior episodes of hypoglycemia may be even lower.
Sources: en.wikipedia.org
== External links == Center for Oral History. "Miguel A. Ondetti". Science History Institute. Bohning, James J. (12 January 1995). Miguel Angel Ondetti, Transcript of an Interview Conducted by James J. Bohning at Princeton, New Jersey on 12 January 1995 (PDF). Philadelphia, PA: Chemical Heritage Foundation. Hall of Fame, Inventor Profile: Miguel Ondetti
Naltrexone, sold under the brand name Revia among others, is a medication primarily used to manage alcohol use and opioid use disorders by reducing cravings and feelings of euphoria associated with substance use disorder. It has also been found to be effective for the treatment of other addictions and may be used for them off-label. The combination naltrexone/bupropion is used to treat obesity. Naltrexone is an opioid antagonist and works by blocking the effects of opioids, including both opioid drugs as well as opioids naturally produced in the brain. It is taken orally or by injection into a muscle. Effects begin within 30 minutes, though a decreased desire for opioids may take a few weeks to occur. Side effects may include trouble sleeping, anxiety, nausea, and headaches. In those still on opioids, opioid withdrawal may occur. Use is not recommended in people with liver failure. It is unclear if use is safe during pregnancy. Naltrexone was first made in 1965 and was approved for medical use in the United States in 1984. It is on the WHO Model List of Essential Medicines. In 2021, it was the 254th most commonly prescribed medication in the United States, with more than 1 million prescriptions.
Despite his clean energy policies and congressional Republicans characterizing them as a "War on American Energy", domestic oil production reached a record high in October 2023. Biden has said the U.S. needs to "get tough" on China, calling it the "most serious competitor" that poses challenges to the United States' "prosperity, security, and democratic values". Biden has spoken about human rights abuses in the Xinjiang region to Chinese leader Xi Jinping, pledging to sanction and commercially restrict Chinese government officials and entities who carry out repression. Biden has said he is against regime change but is for providing non-military support to opposition movements. He opposed direct U.S. intervention in Libya, voted against U.S. participation in the Gulf War, voted in favor of the Iraq War, and supports a two-state solution in the Israeli–Palestinian conflict. Biden pledged to end U.S. support for the Saudi Arabian-led intervention in Yemen and to reevaluate the United States' relationship with Saudi Arabia. Biden supported extending the New START arms control treaty with Russia to limit the number of nuclear weapons deployed by both sides. In 2021, Biden officially recognized the Armenian genocide, becoming the first U.S. president to do so. Biden supported abortion rights throughout his presidency, though he personally opposes abortion because of his Catholic faith. In 2019, he said he supported Roe v. Wade and repealing the Hyde Amendment. After Dobbs v.
Sources: en.wikipedia.org
MOFs have potential as heterogeneous catalysts, although applications have not been commercialized. Their high surface area, tunable porosity, diversity in metal and functional groups make them especially attractive for use as catalysts. Like other heterogeneous catalysts, MOFs may allow for easier post-reaction separation and recyclability than homogeneous catalysts. In some cases, they also give a enhanced catalyst stability. Additionally, they typically offer substrate-size selectivity. Nevertheless, while clearly important for reactions in living systems, selectivity on the basis of substrate size is of limited value in abiotic catalysis, as reasonably pure feedstocks are generally available.Enantiopure chiral ligands or their metal complexes have been incorporated into MOFs to lead to efficient asymmetric catalysts. Even some MOF materials may bridge the gap between zeolites and enzymes when they combine isolated polynuclear sites, dynamic host–guest responses, and a hydrophobic cavity environment. Theoretical calculations show that MOFs are semiconductors or insulators with band gaps between 1.0 and 5.5 eV which can be altered by changing the degree of conjugation in the ligands indicating its possibility for being photocatalysts. Useful comparisons can be made with zeolites, which are extraordinarily useful in catalysis; however, zeolites are limited by the fixed tetrahedral coordination of the Si/Al connecting points and the two-coordinated oxide linkers, and fewer than 200 zeolites are known.
The Prime Minister of Spain at the time, Práxedes Mariano Mateo Sagasta y Escolar, was also a Freemason. It was also in Madrid, and not in Cuba, where José Martí was in the 1870's initiated as a Freemason into Logia Armonía (English: Harmony Lodge).
=== Pakistan === In Pakistan, after completing a MBBS degree and further completing a one year house job, doctors can enroll in two types of postgraduate residency programs. The first is a MS/MD program run by various medical universities throughout the country. It is a 4–5-year program depending upon the specialty. The second is a fellowship program which is called Fellow of College of Physicians and Surgeons Pakistan (FCPS) by the College of Physicians and Surgeons Pakistan (CPSP). It is also a 4–5-year program depending upon the specialty. There are also post-fellowship programs offered by the College of Physicians and Surgeons Pakistan as a second fellowship in subspecialties.
=== Discontinued === Amibegron (SR-58611; SR-58611A) – β3-adrenergic receptor agonist [26] BTG-1640 (ABIO-08/01; ABIO-0801) – undefined mechanism of action [27] Darigabat (CVL-865; PF-06372865; PF-6372865) – GABAA receptor positive allosteric modulator [28] Imagabalin (PD-0332334; PD-332334; PF-00195889) – α2δ subunit-containing voltage-gated calcium channel ligand [29] Naluzotan (PRX-00023) – serotonin 5-HT1A receptor agonist and sigma σ1 receptor agonist [30] Ocinaplon (CL-273547) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/pyrazolopyrimidine [31] Pagoclone (IP-456; Panex; RP-62955) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/cyclopyrrolone [32] PF-572778 – undefined mechanism of action [33] Rufinamide (Banzel; CGP-33101; E-2080; Inovelon; RUF-331; SYN-111) – sodium channel blocker and other actions [34] Talaglumetad (LY-544344) – metabotropic glutamate mGlu2 and mGlu3 receptor agonist (eglumetad prodrug) [35] Tedatioxetine (Lu-AA24530) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), serotonin 5-HT2A, 5-HT2C, and 5-HT3 receptor antagonist, and α1A-adrenergic receptor antagonist [36]
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。